Turn Therapeutics appoints former CDC Director Robert Redfield as Chief Scientific Officer

Turn Therapeutics Inc.

Robert R. Redfield, M.D., former CDC Director, named Chief Scientific Officer effective Sept 9, 2026.
Redfield brings 40+ years in immunology, infectious disease; cited >40,000 times in scientific literature.
He will lead scientific strategy for GX-03 across atopic dermatitis, onychomycosis, hidradenitis suppurativa.
Redfield will work with CEO Bradley Burnam and former FDA Commissioner Stephen Hahn.
Company is clinical-stage biotech developing non-systemic therapies for inflammatory skin diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.